Best Life Sciences Companies in Mississauga, Canada

Developer of skin analysis and assessment systems. The company has developed a non-invasive device called SIAscopy technology which utilizes light to view beneath moles and lesions. It includes software that creates real-time images for doctors and dermatologists for evaluating moles and lesions.

Synaptive Medical develops planning tools and imaging solutions for application in minimally invasive neurosurgery. Its solutions include BrightMatter Prime which enables thorough and systematic pre-operative preparation with training tools, high fidelity images as well as a smooth and seamless workflow into the surgical suite; and BrightMatter™ Servo which unites high-resolution imaging capabilities with hands-free alignment while seamlessly delivering 3D tractography visualization for navigation into the surgical suite. The company acquired FDA clearance for its product BrightMatter Guide which is a 3D neuro-navigation system.

Funding rounds

• Jul 2025Series C—
• Mar 2023Conventional Debt$40M
• Oct 2020Series C$17M
• Dec 2019Series C$25M

Founders & team

Cameron PironCo-FounderWes HodgesCo-Founder

Investors

Linamar, Export Development Canada, General Atlantic, Sensegain Capital, Sissel Technology Development, Espresso Capital

Tech stack

Apple Icloud MailBootstrapCdnjsCloudflareDropboxGoogle Tag Manager

Developer of functional electrical stimulation therapy for upper limb paralysis. The company has developed a therapy called MyndMove based on the concepts of promoting neuroplasticity to improve the voluntary movement of the hand and arm. MyndMove can be used to treat upper extremity paralysis or paresis post-stroke, spinal cord or traumatic brain injury.

Funding rounds

• Feb 2026Post IPO$95K
• Jan 2026Post IPO$90K
• Dec 2025Post IPO$80K
• Oct 2025Post IPO$37.5K

Founders & team

Milos PopovicCo-founder and Director

Investors

TiE Toronto, HTX, FedDev Ontario, Ontario Centre of Innovation, Springboard Enterprises

Aptose Biosciences (formerly Lorus Therapeutics) is developing therapeutics to treat life-threatening cancers such as such as acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS) based on a patient’s specific gene expression signature. It is also creating proprietary companion diagnostic tools to identify predisposed sensitivities to targeted therapies for use as a single-agent or combination regimens. Its lead product, APTO-253 is for the treatment of AML and MDS. APTO-253 is an inducer of the Kruppel-like factor 4 gene (the Klf4 Gene) for patients with advanced hematologic malignancies. Additionally, it also has a preclinical small molecule program, APTO-500, targeting maternal embryonic leucine zipper kinase (MELK) for the treatment of various cancers. Its large molecule program includes a molecule to target specific cell-surface receptors expressed in certain cancers expressing the Interleukin-17E receptor (IL-17ER).

Developer of small molecule drugs to treat cancer and CNS disorders. The company is developing epigenetic medicines targeting HDAC proteins. The company's product includes HDAC6 inhibitors that help in the selective inhibition of disease-relevant HDAC isoforms.

Funding rounds

• Sep 2024Seed$3.2M

Founders & team

Pimyupa ManaswiyoungkulCo-Founder & COONabanita NawarCo-Founder & CEO

Investors

SeedFolio, FACIT, TIAP, Eos, Ontario Centre of Innovation, UTEST

Tech stack

Anime.JsCdnjsCloudflareCloudflare Bot ManagementCore-JsElementor

Acerus Pharma is a developer of drugs for treating urology, hormone replacement therapy & female sexual dysfunction. It markets for the symptomatic relief of menopausal symptoms; Natesto, which uses Acerus licensed nasal gel technology as a testosterone nasal gel. It helps in replacement therapy in adult males diagnosed with hypogonadism. It also market Gynoflor which it has licensed from Medinoba and is approved in 40 countries as a vaginal estrogen therapy with the addition of lactobacillus, for the treatment of atrophic vaginitis.

Developer of various biological products and technological solutions. The company has expertise in virology and protein biochemistry. The Company developed a pipeline of selected biological technologies including VIRUSMAX (Influenza Virus Yield Enhancement Technology), LumiSort (Semen Sexing Technology), and the thrombolytic drug, Kinlytic (Urokinase). The company's core focus is in Infectious Disease Antigen, including cell culture, molecular biology, and others.

NeurAxon is developing NOS inhibiting small molecules for treating migraines and neuropathies. Its primary focus is on developing inhibitors of nitric oxide synthase, an enzyme involved in modulating pain and central nervous system neuronal sensitization. Its lead product candidate, NXN-188 currently in phase 2 and 3 trials is a dual-action small molecule incorporating both nNOS inhibition and 5-HT agonism that is being developed for the treatment of acute migraine. Its other products include NXN-462 in phase 2 trials for treating chronic migraine and neuropathic pain. NXN-677 act on nNOS/iNOS and is in pre-clinical trials for treating inflammatory and severe pains.

Developer of radiopharmaceuticals to treat cancer. The company uses CanSEEK technology to minimize toxicity caused by off-target delivery to activate radiopharmaceuticals targeting moiety, such as its ligand. The company's pipeline includes PNT2002 a PSMA-Targeted therapy for metastatic castration-resistant prostate cancer (mCRPC) and PNT2001 is a next-generation PSMA-targeted radioligand.

Funding rounds

• Aug 2020Series A$20M

Founders & team

Joe MccannCEO

Therapure Biopharma focuses on manufacturing complex biologics and on developing, manufacturing, and selling its blood and plasma-related therapeutic products. It operates through three divisions: Therapure Biomanufacturing (Mammalian cell line based CDMO), Therapure Biologics (Plasma-derived products), and Therapure Innovations (Proprietary drug development). It provides contract development and manufacturing services for integrated biologics and also offers drug discovery, research, and development services. The company also focuses on the development of a portfolio of its own plasma-derived protein therapeutics through its technology, PlasmaCap EBA (for efficient capture of plasma proteins at high yields and purities). Therapure Innovations' lead candidates TBI 302 (liver cancer) and TBI 304H (anemia) are undergoing phase I trials while TBI 301 (Hep C) is in the discovery stage. The company is funded by the Catalyst Capital Group since its inception. The company's CDMO business and certain rights to their plasma products and technology for the Chinese market were acquired by a JV between 3SBio and CPE funds.

Novadaq Technologies develops and markets clinical solutions for fluorescence imaging. It has three main products. SPY Elite enables surgeons to visualize and monitor microvascular blood flow and perfusion in tissue intraoperatively. More than 190 peer-reviewed publications have demonstrated that the use of SPY during complex surgery such as coronary artery bypass, breast and other reconstruction and lower anterior colon resection leads to fewer postoperative complications and lower hospital costs. The PINPOINT system allows for endoscopic fluorescence imaging. The LUNA system enables surgeons to visualize blood vessel and tissue perfusion during angiographies. LUNA provides clinicians with real-time visualization of tissue perfusion in patients being evaluated and treated for the effects of certain cardiovascular disease that impair blood flow to extremities and other tissues. Such conditions may include diabetic foot ulcers, pressure ulcers & chronic wounds.The ability to visualize perfusion in a lower extremity can assist physicians in defining the optimal patient care pathway and may maximize limb salvage. In addition, it also has manufactures DermACELL, a decellularized tissu

CellAegis Devices is developing the autoRIC device, a non-invasive, portable and automated device, for Chronic Remote Ischemic Conditioning (CRIC - brief episodes of no blood flow in a limb followed by resumed blood flow) following Acute Myocardial Infarction. The autoRIC device provides point-of-care delivery of RIC. It is intended to provide RIC to adult patients over 18 years of age undergoing cardiothoracic surgery or interventional cardiothoracic procedures or patients with evolving myocardial infarction. The device has received CE Mark and Health Canada approval but an investigational device in the US as of January 2018.